Gain Therapeutics, Inc. (GANX)
NASDAQ: GANX · Real-Time Price · USD
1.160
-0.020 (-1.69%)
Nov 18, 2026, 1:36 PM EST - Market open
Gain Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
21
Market Cap
51.65M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 55.18K | -84.93K | -60.62% |
| Dec 31, 2022 | 140.11K | -24.89K | -15.08% |
| Dec 31, 2021 | 164.99K | 136.11K | 471.29% |
| Dec 31, 2020 | 28.88K | -12.42K | -30.07% |
| Dec 31, 2019 | 41.30K | 20.69K | 100.40% |
| Dec 31, 2018 | 20.61K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Heron Therapeutics | 148.22M |
| Xilio Therapeutics | 55.01M |
| Spero Therapeutics | 41.56M |
| Verrica Pharmaceuticals | 22.89M |
| Werewolf Therapeutics | 21.00M |
| RenovoRx | 2.78M |
| Impact BioMedical | 38.00K |
GANX News
- 21 hours ago - Gain Therapeutics Presents Clinical Data from Phase 1b Study of Rexaceract and Preclinical Data from Novel GCase Modulator GT-04686 - GlobeNewsWire
- 6 days ago - Gain Therapeutics price target lowered to $5 from $8 at Roth Capital - TheFly
- 7 days ago - Gain Therapeutics Earnings release: Q3 2026 - Filings
- 7 days ago - Gain Therapeutics Quarterly report: Q3 2026 - Filings
- 8 days ago - Gain Therapeutics reports Q3 EPS (7c), consensus (13c) - TheFly
- 8 days ago - Gain Therapeutics Reports Financial Results for Third Quarter 2026 and Provides Corporate Update - GlobeNewsWire
- 8 days ago - Gain Therapeutics Slides: Corporate presentation - Filings
- 13 days ago - Gain Therapeutics Announces Late-Breakers and Poster Presentations at Upcoming Scientific Conferences - GlobeNewsWire